Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) registered a 5.71% increase, still its new closing price is 24.37% up from the company’s 1 year high of 3.33.It posted 0.68% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 4 stock analysts following this company have an average price target at $5.00, with individual PT in the $4.00-$6.00 range. The shares moved at $1.48, implying that brokerage firms see shares losing about -17.78% in twelve months time.
Idera Pharmaceuticals, Inc. (IDRA) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -1.33% fall year to date. A Director at Idera Pharmaceuticals, Inc. (IDRA) acquired shares in a transaction closed on Friday October 07, 2016. BAKER JULIAN bought 3,250,000 shares in the company at $2 each and collected $6,500,000 in proceeds. BAKER JULIAN now owns 9,420,343 shares in the company after this transaction. A Director, 10% Owner in the company, ZEIN YOUSSEF EL, disclosed a transaction on Monday October 03, 2016 that ended up paying $10,001 from the purchase of 4,228 shares at $2.56 per share.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Upcoming Results on Tap
Idera Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.12 in that period. Sales during the quarter are predicted to arrive at $0.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.10. The mean forecast was for $0 and $-0.12 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.11/share.
Idera Pharmaceuticals, Inc. (IDRA) Brokerage Update
Idera Pharmaceuticals, Inc. (IDRA) is in Rodman & Renshaw’s research list so their analyst rating change is noteworthy. These shares were upgraded to Mkt Outperform from Mkt Perform by Rodman & Renshaw, according to news reported on Wednesday March 24, 2010.Another important research note was issued by Susquehanna Financial on Monday October 27, 2008.The firm upgraded IDRA to Neutral from Negative. Over the last six months and over the last three months, the shares of Idera Pharmaceuticals, Inc. (IDRA), have changed -15.43% and -4.52%, respectively.
